If you want to get inside of your pet's head, the tech hasn't arrived yet, but one company hopes to have it trending in the right direction.
Los Angeles-based FluentPet has developed a series of tiles it claims help four-legged companions communicate with their humans. Through training, they can learn to associate various tiles with words they've learned over time and then use their paws to press them.
The tech has been a hit on platforms like TikTok, where tons of "talking dog" videos have gone viral.
There are a wide range of options to select from when it comes to purchasing the tech. Test kits start out around $35 with the most expensive option, They Can Talk Kit, being priced around $230.
The company also recently launched FluentPet Connect, which integrates the tile button system into an app. This helps keep pet owners connected to their pets at all times. If a person isn't home, their pet could send an alert, similar to a text message.
The system is available for an additional $69.99 but is compatible with tiles that have already hit the market.
However, devices like FluentPet and the studies that have been done with their subjects do face skepticism from scientists. Clive Wynne, the founding director of the Canine Science Collaboratory at Arizona State University, explained that rather than language comprehension, the dogs are being conditioned.
“This is one of the most basic forms of learning in the animal kingdom," Wynne told the Washington Post. "The dog forms an association between an action and an outcome that it desires.”
Filing your taxes should be easy and straightforward if your documents are together — but what about if you became a new cryptocurrency or retail investor? What if you worked remotely last year, and not in the same state as your employer? What if you received a pandemic stimulus check, or are eligible for the child tax credit? Luis Rivero, CPA and Director of Tax at Taxfyle, joins Closing Bell to discuss what exactly all taxpayers need to know, whether they hold crypto investments, worked out of state, have children, and more.
Two years after the pandemic began, vaccines are widespread, but COVID-19 treatments aren't as plentiful. RedHill Biopharma is working to change that with its easy-to-take coronavirus treatments — which come in pill form and treat cases ranging from mild to severe. Guy Goldberg, Chief Business Officer at RedHill Biopharma, joins Closing Bell to discuss the company's two COVID-19 treatments in trial, pricing once the drugs are widely available, the company's latest earnings results, and more.
Christopher Wolfe, CIO at First Republic Private Wealth Management, joins Cheddar News' Closing Bell, where he says he is surprised that the first quarter was the first down period in a long time, but adds that the second quarter could be difficult with a lot of volatility expected.
Jeffrey Small, President of Arbor Financial, joins Chedar News' Closing Bell, where he breaks down why stocks closed near session lows on Wednesday and tells viewers what to expect ahead of next earnings season.
